Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.
Next-generation sequencing (NGS) and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer. Illumina works with cancer epigenetics experts to ensure its NGS and array solutions meet the field's rapidly evolving needs.
Aberrant methylation is a common epigenetic alteration in cancer. NGS enables researchers to identify and compare methylation in cancer vs. normal cells, and gain insight into methylation patterns at a single nucleotide level.Learn More About Methylation Sequencing
Methylation arrays enable epigenome-wide association studies that can analyze multiple cancer samples in parallel. Arrays quantitatively interrogate methylation sites across the genome, providing researchers with insight into the regulation of cancer-related genes and pathways.Learn More About Methylation Arrays
Se Hoon Kim, MD, PhD explains how combining NGS panels with methylation microarrays can deliver value in tumor characterization for clinical research.Read Interview
Researchers investigate the epigenetics behind cancer development and metastasis using methylation microarrays and NGS.Read Interview
Researchers identify genomic alterations associated with a deadly oral cancer, including somatic and germline variants as well as changes in promoter methylation and transcription.Read Interview
Altered transcription factor binding is another common epigenetic change linked to cancer. Chromatin immunoprecipitation sequencing (ChIP-Seq) can provide a genome-wide snapshot of DNA-associated protein activity in cancer vs. normal cells.
The method offers hypothesis-free insights into the regulation of gene expression. Deep sequencing enables detection of lower-abundance protein-DNA interactions often observed with transcription factors.Learn More About ChIP-Seq
A method that maps open chromatin regions helps researchers gain a better understanding of the epigenome and its impact on cancer and autoimmune diseases.Read Article
By: Dr. Phil Febbo, Chief Medical Officer at IlluminaRead Article
Optimizing NextSeq 500 System and TruSeq RNA Exome Kit RNA sequencing workflows for lncRNA biomarker identification.Read Interview
By: Sandra Balladares, Ph.D., Global Marketing Manager at IlluminaRead Article
Researchers use an Illumina methylation array on tumor and PBLs to identify differences in breast tumor development between African American and non-African American women.Read Publication
A methylation fingerprint is used to stratify medulloblastoma subgroups for improved characterization.Read Publication
A review of recent epigenetic discoveries in prostate cancer, highlighting their potential as biomarkers for diagnosis, segmentation, and monitoring.Read Publication